Usability of the Ranibizumab 0.5 mg Prefilled Syringe: Human Factors Studies to Evaluate Critical Task Completion by Healthcare Professionals

Reference

1. 1.↵
   1. Busbee B. G.,
   2. Ho A. C.,
   3. Brown D. M.,
   4. Heier J. S.,
   5. Suñer I. J.,
   6. Li Z.,
   7. Rubio R. G.,
   8. Lai P.

   ; HARBOR Study Group. Twelve-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration. Ophthalmology 2013, 120 (5), 1046–1056.

   OpenUrlCrossRefPubMedWeb of Science
2. 2.↵
   1. Nguyen Q. D.,
   2. Brown D. M.,
   3. Marcus D. M.,
   4. Boyer D. S.,
   5. Patel S.,
   6. Feiner L.,
   7. Gibson A.,
   8. Sy J.,
   9. Rundle A. C.,
   10. Hopkins J. J.,
   11. Rubio R. G.,
   12. Ehrlich J. S.

   ; RISE and RIDE Research Group. Ranibizumab for Diabetic Macular Edema: Results from 2 Phase III Randomized Trials: RISE and RIDE. Ophthalmology 2012, 119 (4), 789–801.

   OpenUrlCrossRefPubMedWeb of Science
3. 3.↵
   1. Brown D. M.,
   2. Campochiaro P. A.,
   3. Singh R. P.,
   4. Li Z.,
   5. Gray S.,
   6. Saroj N.,
   7. Rundle A. C.,
   8. Rubio R. G.,
   9. Murahashi W. Y.

   ; CRUISE Investigators. Ranibizumab for Macular Edema Following Central Retinal Vein Occlusion: Six-Month Primary End Point Results of a Phase III Study. Ophthalmology 2010, 117 (6), 1124–1133.e1.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Campochiaro P. A.,
   2. Heier J. S.,
   3. Feiner L.,
   4. Gray S.,
   5. Saroj N.,
   6. Rundle A. C.,
   7. Murahashi W. Y.,
   8. Rubio R. G.

   ; BRAVO Investigators. Ranibizumab for Macular Edema Following Branch Retinal Vein Occlusion: Six-Month Primary End Point Results of a Phase III Study. Ophthalmology 2010, 117 (6), 1102–1112.e1.

   OpenUrlCrossRefPubMedWeb of Science
5. 5.↵
   Genentech, Inc., a member of the Roche Group. Lucentis [package insert]. 2018. https://www.gene.com/download/pdf/lucentis_prescribing.pdf. Accessed June 25, 2018.
6. 6.↵
   Novartis Pharmaceuticals UK Ltd. Lucentis^® 10 mg/ml solution for injection in pre-filled syringe: summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000715/WC500043546.pdf. Accessed June 25, 2018.
7. 7.↵
   U.S. Food and Drug Administration (FDA) and Center for Devices and Radiological Health (CDRH). Applying Human Factors and Usability Engineering to Medical Devices. Guidance for Industry and Food and Drug Administration Staff. 2016. http://www.fda.gov/downloads/MedicalDevices/…/UCM259760.pdf. Accessed August 18, 2016.
8. 8.↵
   ISO IEC 62366-1:2015 Medical Devices—Part 1: Application of usability engineering to medical devices. https://www.iso.org/obp/ui/#iso:std:63179:en.2015. Accessed June 13, 2018.
9. 9.↵
   1. Buerke B.,
   2. Puesken M.,
   3. Mellmann A.,
   4. Seifarth H.,
   5. Heindel W.,
   6. Wessling J.

   Microbiologic Contamination and Time Efficiency of Use of Automatic MDCT Injectors with Prefilled Syringes: Results of a Clinical Investigation. AJR Am. J. Roentgenol. 2010, 194 (2), 299–303.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Giunta M.,
    2. Lalonde L.,
    3. Cordahi G.,
    4. Saurel P.,
    5. Scarino A.

    Syringe Preparation Time of Ranibizumab Prefilled Syringe Versus Ranibizumab and Aflibercept Vials in Clinical Practice: A Canadian Study. Presented at the 7th World Congress on Controversies in Ophthalmology (COPHy), March 31–April 3, 2016, Warsaw, Poland.
11. 11.↵
    1. Souied E.,
    2. Nghiem-Buffet S.,
    3. Leteneux C.,
    4. Bayer S.,
    5. Derveloy A.,
    6. Sagkriotis A.,
    7. Becker G.,
    8. Cohen S. Y.

    Ranibizumab Prefilled Syringes: Benefits of Reduced Syringe Preparation Times and Less Complex Preparation Procedures. Eur. J. Ophthalmol. 2015, 25 (6), 529–534.

    OpenUrl
12. 12.↵
    1. Subhi Y.,
    2. Kjer B.,
    3. Munch I. C.

    Prefilled Syringes for Intravitreal Injection Reduce Preparation Time. Dan. Med. J. 2016, 63 (4), A514.

    OpenUrl
13. 13.↵
    1. Freund K. B.,
    2. Laud K.,
    3. Eandi C. M.,
    4. Spaide R. F.

    Silicone Oil Droplets Following Intravitreal Injection. Retina 2006, 26 (6), 701–703.

    OpenUrlCrossRefPubMedWeb of Science
14. 14.↵
    1. Bakri S. J.,
    2. Ekdawi N. S.

    Intravitreal Silicone Oil Droplets after Intravitreal Drug Injections. Retina 2008, 28 (7), 996–1001.

    OpenUrlCrossRefPubMedWeb of Science
15. 15.↵
    1. Scott I. U.,
    2. Oden N. L.,
    3. VanVeldhuisen P. C.,
    4. Ip M. S.,
    5. Blodi B. A.,
    6. Antoszyk A. N.

    SCORE Study Report 7: Incidence of Intravitreal Silicone Oil Droplets Associated with Staked-On vs Luer Cone Syringe Design. Am. J. Ophthalmol. 2009, 148 (5), 725–732.e7.

    OpenUrlCrossRefPubMedWeb of Science
16. 16.↵
    American Society for Retina Specialists. Clinical Updates: OMIC Releases New Consent Forms That Include a Warning of Possible Silicone Oil Droplet Floaters. August 31, 2016. https://www.asrs.org/education/clinical-updates. Accessed November 15, 2016.
17. 17.↵
    American Society for Retina Specialists. Clinical Updates: Member Alert: Silicone Oil Droplets. August 16, 2016. https://www.asrs.org/education/clinical-updates. Accessed November 15, 2016.
18. 18.↵
    American Society for Retina Specialists. Clinical Updates: Member Alert: Silicone Oil Droplets. July 21, 2016. https://www.asrs.org/education/clinical-updates. Accessed November 15, 2016.
19. 19.↵
    1. Badkar A.,
    2. Wolf A.,
    3. Bohack L.,
    4. Kolhe P.

    Development of Biotechnology Products in Pre-Flled Syringes: Technical Considerations and Approaches. AAPS PharmSciTech. 2011, 12 (2), 564–572.

    OpenUrlPubMed